Skip to main content
TipRanks
Go Ultimate75% OFF

Verrica Pharmaceuticals (VRCA) Q3 2026 Earnings Report

491 Followers

VRCA Q3 2026 EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.50
Beat/Miss
Missed by -$0.08
One Year Ago EPS
-$0.03

VRCA Q3 2026 Revenue Results

Actual Revenue
$6.91M
Expected Revenue
$6.20M
Beat/Miss
Beat by +$714.00K
YoY Revenue Growth
-51.80%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
VRCA Upcoming Earnings

Verrica Pharmaceuticals's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

VRCA Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-22.45%|
Earnings Call Sentiment|Positive

The call was predominantly positive, supported by record U.S. YCANTH revenue, strong year-over-year product growth, improving prescription yield, meaningful progress in the common warts Phase III program, secured financing, and encouraging VP-315 data and development opportunities. Offsetting factors included a sequential unit decline attributed to seasonality, expected fourth-quarter seasonality, a wider net loss, higher research and development expenses, lower licensing revenue versus a milestone-inflated prior-year period, and unresolved timing and design questions for the Gorlin syndrome program.

Company Guidance

Management expects COVE-2 top-line data in the first quarter of 2027 and COVE-3 top-line data by mid-2027, with Torii funding the first $40 million, representing approximately 90% of the current program budget; assuming utilization of the remaining $15 million available under the credit facility, cash runway could extend beyond the key data readouts for common warts and into the fourth quarter of 2027. For YCANTH, management expects “normal seasonality patterns” in Q4, aims to drive the conversion rate into Q4 and “mature that in 2027,” and expects ex-U.S. revenue going forward to be “similar, but probably a little less” as production shifts to Japan and revenue moves to a royalty basis; coverage currently includes 95 million lives under pharmacy and 137 million under medical, with “about a 50-50 split” between medical benefit and pharmacy benefit. The company is pushing to submit a common-warts filing “as quickly as possible” after the mid-2027 data, while the Gorlin syndrome proof-of-concept study design, protocol, cost and timelines remain under development.

  • Record YCANTH Product Revenue and Strong Year-Over-Year GrowthThird-quarter total revenue was $6.9 million, including record U.S. YCANTH net product revenue of $5.7 million. U.S. YCANTH net product revenue increased approximately 11.9% from the second quarter and 57.9% from the third quarter of last year.
  • Expansion of YCANTH Demand and DistributionDispensed YCANTH applicator units totaled 19,135 in the third quarter, up 35.8%, or 5,042 units, from the third quarter of last year. Management attributed the year-over-year growth to expanded distribution through specialty and retail pharmacy channels and continued penetration into high-volume dermatology, pediatric, and primary care prescribers.
  • Improved Prescription Yield and Commercial ExecutionManagement reported an improvement in yield per prescription during the third quarter from initiatives including the YCanthRx non-dispensing pharmacy option, prescription-retargeting and segmentation work, efforts to reduce prescription leakage, and efforts to optimize insurance coverage. The company said it expects further yield accretion as these strategies are implemented at scale.
  • Broad YCANTH Coverage AccessManagement cited approximately 95 million lives covered under pharmacy benefits and 137 million under medical benefits, with about a 50-50 split between medical and pharmacy benefits. The company said many medical claims have no prior authorization and few restrictions, with the key focus being routing prescriptions to in-network pharmacies that can obtain reimbursement.
  • Positive Molluscum Efficacy AnalysesNew analyses from YCANTH's two registrational Phase III molluscum trials showed that YCANTH-treated patients achieved complete clearance at a rate approximately 4 times faster than placebo-treated patients, while 3 times as many YCANTH-treated patients achieved complete clearance at each treatment visit.
  • Continued Commercial Adoption and Awareness EffortsManagement reported that prescriber targeting and segmentation are moving prescribers from the 'dabbler' phase toward stronger adoption and 'loyalist' status, with a robust conversion rate in the third quarter. The company also cited increasing awareness among physicians and families regarding the benefits of treating molluscum rather than following a watch-and-wait approach.
  • Progress in Common Warts Phase III ProgramEnrollment was completed in COVE-2, the first pivotal Phase III trial of YCANTH for common warts, after an interim promising-zone analysis indicated that no additional patients were needed. COVE-3, the second pivotal trial, exceeded 50% of its current enrollment target and was enrolling ahead of schedule.
  • Upcoming Common Warts Data ReadoutsTop-line data from COVE-2 are expected in the first quarter of 2027, and top-line data from COVE-3 are expected by mid-2027.
  • Substantial Partner Funding for Common Warts ProgramTorii Pharmaceutical is funding the first $40 million of the common warts trial costs, representing approximately 90% of the current program budget. Research and development expenses for the program have been non-cash to date and are expected to remain non-cash until Torii's funding commitment is exhausted toward the end of the program.
  • Common Warts Market OpportunityManagement stated that common warts affect approximately 22 million people in the U.S. alone and that there are no FDA-approved prescription therapies. The company believes a YCANTH label expansion into common warts could represent a multibillion-dollar commercial opportunity and could benefit from overlap between clinicians treating molluscum and common warts.
  • Credit Facility Milestones AchievedVerrica achieved the predefined revenue, growth, and operational milestones under its August credit facility, unlocking the remaining $15 million of borrowing commitment. The facility has a maximum commitment of $27.5 million, of which $12.5 million was immediately available and has been borrowed.
  • Funding Supports Common Warts Data ReadoutsManagement said the additional non-dilutive capital available under the credit facility is expected to allow the company to complete both pivotal common warts studies and evaluate their data. Assuming utilization of the remaining $15 million, the company believes its cash runway could extend beyond the key common warts data readouts and into the fourth quarter of 2027.
  • Improved Gross Product MarginGross product margin increased to 89.8% in the third quarter of 2026 from 79.1% in the third quarter of 2025. Cost of product revenue was $0.6 million compared with $0.8 million in the prior-year quarter.
  • Reduced Interest ExpenseInterest expense declined to $0.3 million from $2.1 million in the same period last year, a decrease of $1.8 million related to the settlement and termination of the OrbiMed debt facility in November 2025.
  • VP-315 Sporadic BCC Phase II ResultsIn the previously disclosed Phase II study of VP-315 for sporadic basal cell carcinoma, injections produced a 97% objective response rate and an average 86% reduction in tumor size in treated lesions. Histological confirmation of complete clearance was observed in more than half of the subjects.
  • Potential Abscopal Effects of VP-315Untreated lesions in the sporadic BCC study, including some distant from the primary injection site, shrank by an average of 67%. Three of 14 lesions in patients with additional untreated lesions cleared completely, which management said suggested a potential abscopal response.
  • Exploration of VP-315 in Gorlin SyndromeVerrica is exploring a proof-of-concept study of VP-315 in patients with Gorlin syndrome, a rare genetic disease associated with dozens to hundreds of basal cell carcinomas over a patient's lifetime and no FDA-approved therapy specifically for the condition. The company has clinical supply manufactured and is finalizing the study design, protocol, budget, and timelines.
  • Regulatory Alignment for Sporadic BCCVerrica said it reached agreement with the FDA on the design of a Phase III program for sporadic BCC consisting of two 100-patient placebo-controlled studies with long-term follow-up after approval. The FDA also specifically asked the company to include Gorlin patients in its Phase III protocol.
  • Potential Complementary Role for VP-315Management stated that VP-315 acts independently of the hedgehog pathway and may provide a lytic effect on existing lesions along with a potential immunologic or abscopal effect. The company said VP-315 could potentially complement hedgehog-pathway therapies that focus on reducing the occurrence of new lesions.
  • International YCANTH Expansion ActivityFollowing the exclusive distribution, marketing, and supply agreement with Medomie Pharma, Verrica is supporting preparation activities for regulatory approval and commercialization of YCANTH in Israel. Management also reported continued interest from potential partners around the world.

VRCA Earnings History

VRCA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.58--0.57――
Nov 12, 20262026 (Q3)-0.50-0.58-0.03-1833.33% (-0.55)
Aug 06, 20262026 (Q2)-0.39-0.620.02-3200.00% (-0.64)
May 12, 20262026 (Q1)-0.36-0.45-155.00% (+0.55)
Mar 11, 20262025 (Q4)-0.79-0.57-2.476.25% (+1.83)
Nov 14, 20252025 (Q3)-0.06-0.03-4.999.39% (+4.87)
Aug 12, 20252025 (Q2)-0.700.02-3.7100.54% (+3.72)
May 13, 20252025 (Q1)-1.23-1.00-4.477.27% (+3.40)
Mar 11, 20252024 (Q4)-2.52-2.40-5.354.72% (+2.90)
Nov 04, 20242024 (Q3)-3.76-4.90-5.49.26% (+0.50)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed